Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands		Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	[1]	$ 221,217	$ 96,907
Accounts receivable, net	[1]	26,980	19,969
Inventory, net	[1]	20,519	16,604
Prepaid expenses and other current assets	[1]	9,623	9,389
Total current assets	[1]	278,339	142,869
Property, plant, equipment, and investment properties, net	[1]	23,405	16,411
Intangible assets, net	[1]	94,247	62,649
In-process research and development	[1]	812,446	793,152
Goodwill	[1]	289,607	224,292
Investments, net	[1]	21,434	22,453
Other assets	[1]	6,013	5,838
Total assets	[1]	1,525,491	1,267,664
Current liabilities:
Accounts payable	[1]	16,039	8,744
Accrued expenses	[1]	149,843	60,912
Current portion of lines of credit and notes payable	[1]	14,599	13,455
Total current liabilities	[1]	180,481	83,111
2033 Senior Notes, net of discount and estimated fair value of embedded derivatives	[1]	109,203	131,454
Other long-term liabilities, principally deferred revenue and deferred tax liabilities	[1]	408,821	217,358
Total long-term liabilities	[1]	518,024	348,812
Total liabilities	[1]	698,505	431,923
Equity:
Common Stock - $0.01 par value, 750,000,000 shares authorized; 464,567,632 and 433,421,677 shares issued at June 30, 2015 and December 31, 2014, respectively	[1]	4,646	4,334
Treasury Stock - 1,120,367 and 1,245,367 shares at June 30, 2015 and December 31, 2014, respectively	[1]	(3,645)	(4,051)
Additional paid-in capital	[1]	1,687,389	1,529,096
Accumulated other comprehensive income (loss)	[1]	(18,880)	(12,392)
Accumulated deficit	[1]	(834,721)	(674,843)
Total shareholders’ equity attributable to OPKO	[1]	834,789	842,144
Noncontrolling interests	[1]	(7,803)	(6,403)
Total shareholders’ equity	[1]	826,986	835,741
Total liabilities and equity	[1]	$ 1,525,491	$ 1,267,664

[1] As of June 30, 2015 and December 31, 2014, total assets include $7.1 million and $7.6 million, respectively, and total liabilities include $12.7 million and $12.1 million, respectively, related to SciVac Ltd (“SciVac”), now known as SciVac Therapeutics, Inc., a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.